Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 January 2022 - 08:05AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the 40th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m.
E.T.
A live webcast of the Company presentation will be available
through the investor relations section of the Company's website
at www.akerotx.com. Following the live webcasts, archived
replays will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including non-alcoholic steatohepatitis (NASH), a
disease without any approved therapies. Akero's lead product
candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion
protein that has been engineered to mimic the balanced biological
activity profile of native FGF21, an endogenous hormone that
alleviates cellular stress and regulates metabolism throughout the
body. EFX is designed to offer convenient once-weekly subcutaneous
dosing. The consistency and magnitude of observed effects position
EFX to be a potentially best-in-class medicine, if approved, for
treatment of NASH. EFX is currently being evaluated in two Phase 2b
clinical trials: the HARMONY study in pre-cirrhotic patients with
F2/F3 fibrosis and the SYMMETRY study in compensated cirrhotic (F4)
patients. Akero is headquartered in South San Francisco. Visit us
at www.akerotx.com for more information.
Investor Contact:Christina TartagliaStern
Investor Relations,
Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:650.487.6488media@akerotx.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2023 to Mar 2024